AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
3min snip
The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)
ACQ2 by Acquired
Exploring the Mechanisms of Lerakotide and Semagotide in Obesity Treatment
Lerakotide and semagotide reduce energy intake by 15% and 30% respectively, primarily targeting the brain to affect hunger, satiety, and the reward system. Animal studies help to pinpoint the receptors in the brain that these medications act on. Patients experience reduced calorie intake, better control of eating, and decreased cravings for savory foods like burgers. Although the exact mechanisms in the brain are not fully understood, the majority of the effect is in the brain. The presence of natural GLP-1 in the brain is not significantly different between individuals with and without diseases, raising questions about how lerakotide and semaglutide with longer half-lives might impact brain penetration.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode